---
title: "Sanofi's Extraintestinal Pathogenic E. Coli Vaccine Fails To Show Sufficient Efficacy In Phase 3 Clinical Study"
date: "2025-02-13 14:09:42"
summary: "Sanofi SA :PRESS RELEASE: UPDATE ON EXTRAINTESTINAL PATHOGENIC E. COLI VACCINE PHASE 3 CLINICAL STUDYVACCINE CANDIDATE FAILS TO SHOW SUFFICIENT EFFICACYNO SAFETY SIGNALS IDENTIFIED FOR E. COLI VACCINE CANDIDATEE.MBRACE PHASE 3 STUDY DISCONTINUEDRECORDS $250 MILLION IMPAIRMENT CHARGE IN Q4 2024FULL-YEAR IFRS EPS ADJUSTED TO €4.44 FROM €4.59MAINTAINS 2025 FINANCIAL GUIDANCE..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Sanofi SA :

* PRESS RELEASE: UPDATE ON EXTRAINTESTINAL PATHOGENIC E. COLI VACCINE PHASE 3 CLINICAL STUDY
* VACCINE CANDIDATE FAILS TO SHOW SUFFICIENT EFFICACY
* NO SAFETY SIGNALS IDENTIFIED FOR E. COLI VACCINE CANDIDATE
* E.MBRACE PHASE 3 STUDY DISCONTINUED
* RECORDS $250 MILLION IMPAIRMENT CHARGE IN Q4 2024
* FULL-YEAR IFRS EPS ADJUSTED TO €4.44 FROM €4.59
* MAINTAINS 2025 FINANCIAL GUIDANCE

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_TUAB58LRX:0-sanofi-s-extraintestinal-pathogenic-e-coli-vaccine-fails-to-show-sufficient-efficacy-in-phase-3-clinical-study/)
